{
  "docId": "019de070-a7f9-700d-9686-c0d9e2559ea7",
  "docSlug": "49e1302a11c2e640ac427a516c932653",
  "documentTitle": "Bausch Health Companies | Results Presentation Deck | 82 slides",
  "authorId": "bausch-health-companies",
  "authorName": "Bausch Health",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 49,
  "pageCount": 82,
  "prevPage": 48,
  "nextPage": 50,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 60,
  "notes": "Includes specific commentary on product-level revenue drivers and LOE impacts.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-a7f9-700d-9686-c0d9e2559ea7/49",
  "deckHref": "/decks/019de070-a7f9-700d-9686-c0d9e2559ea7",
  "deckJsonHref": "/decks/019de070-a7f9-700d-9686-c0d9e2559ea7.json",
  "deckAnchorHref": "/decks/019de070-a7f9-700d-9686-c0d9e2559ea7#slide-49",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.225,
        "x": 0.758,
        "y": 0.165
      },
      "kind": "callout",
      "text": "+13% WELLBUTRIN/APLENZIN combined reported revenue growth vs. YTD19; driven by WELLBUTRIN, which saw 11% reported revenue growth vs. FY19. FY20, Diversified Products business unit had an LOE revenue drag of $98M.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea2caecb-d055-4ad0-8afa-57b7150bb528",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.075,
        "w": 0.725,
        "x": 0.258,
        "y": 0.915
      },
      "kind": "source-note",
      "text": "1. See Slide 2 and Appendix for further non-GAAP information. 2. See Appendix for further information on the use and calculation of constant currency. 3. Organic growth/change... 4. See the Appendix for details on amortization... 5. U.S. sales only.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31e2e33a-b939-4595-aad7-a3aaec11107a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.685,
        "w": 0.697,
        "x": 0.053,
        "y": 0.158
      },
      "kind": "table",
      "text": "Financial performance table comparing 12.31.20 vs 12.31.19 across revenue, expenses, and margins.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b211559f-640b-4bb9-9418-93a1353ca87d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.375,
        "x": 0.201,
        "y": 0.065
      },
      "kind": "title",
      "text": "Financial Results",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a95a997-65f3-4865-837c-37c7490bf64f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "579d4394-2832-4286-b476-7ed066c7f461",
      "evidence": "Financial performance table comparing 12.31.20 vs 12.31.19 across revenue, expenses, and margins.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}